Pyridoxal phosphatase is a novel cancer autoantigen in the central nervous system

AS Bøe*,1, G Bredholt2, PM Knappskog2, A Storstein3, CA Vedeler2 and ES Husebye1
1Division of Endocrinology, Institute of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway; 2Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Norway; 3Department of Neurology, Haukeland University Hospital, N-5021 Bergen, Norway

Autoantibodies against many proteins are common in sera from patients with various types of cancer. These antibodies are sometimes involved in the development of conditions associated with cancer, such as paraneoplastic neurologic disorders. We used a human brain cDNA expression library and serum from a paraneoplastic neurologic disorder patient to search for new autoantigens in the nervous system. Pyridoxal phosphatase was identified as a novel autoantigen. Expression studies showed that pyridoxal phosphatase was strongly expressed in various parts of the central nervous system. Sera contained antibodies against pyridoxal phosphatase in 22 of 243 (9.1%) patients with lung cancer and eight of 113 (7.1%) with other forms of cancer vs two of 88 (2.3%) healthy control subjects. In addition, 2–4% of patients with different autoimmune diseases had autoantibodies against pyridoxal phosphatase. None of the antipyridoxal phosphatase-positive patients were known to have a paraneoplastic neurologic disorder. Hence, autoantibodies against pyridoxal phosphatase correlate with cancer but not necessarily with the subset of patients with paraneoplastic neurological disorders although serum from such a patient was used to screen the cDNA library. This study showed that yet another enzyme involved in pyridoxal 5′-phosphate metabolism is an autoantigen. Thus, pyridoxal 5′-phosphate seems to be a common denominator for autoantigens involved in autoimmune diseases.

British Journal of Cancer (2004) 91, 1508–1514. doi:10.1038/sj.bjc.6602142 www.bjcancer.com
Published online 28 September 2004
© 2004 Cancer Research UK

Keywords: autoimmunity; pyridoxal 5′-phosphate; pyridoxal phosphatase

Antibodies against nontissue specific intracellular or cell-surface proteins are seen in several types of cancer, such as antibodies against p53 (Crawford et al, 1982), oncogene products such as ras (Cheever et al, 1995), cellular proteins such as p62 (Zhang et al, 1999) and cell cycle proteins such as cyclin B1 (Covini et al, 1997). Other malignant conditions are characterised by autoantibodies against tissue-restricted proteins, as seen in patients with paraneoplastic neurologic disorders (PND). These patients produce antibodies and cytotoxic T cells that target neuron-specific proteins abnormally expressed in non-neuronal tumours causing neuronal injury (Dalmau and Posner, 1997; Bataller and Dalmau, 2003). The pathogenic role of onconeural autoantibodies is often unclear. In other cases, such as Lambert–Eaton myasthenic syndrome, antibodies are directly involved in pathogenesis, such as by blocking voltage-gated calcium channels and causing neuromuscular conduction blockade (Lang et al, 1981).

Detection of circulating autoantibodies signals the presence of malignant disease, often at an early stage (Trivera et al, 1995, 1996), and assay of cancer-associated antibodies can be used in diagnosing cancer. Further, an immune response against the tumour should theoretically help in controlling tumour growth. Souza et al (2003) have recently shown that patients with previous autoimmune thyroid disease and well-differentiated thyroid cancer have a better prognosis than those without signs of thyroid autoimmunity.

By using serum from a patient with known PND, we screened a human brain cDNA expression library to identify novel cancer-related or paraneoplastic autoantigens. One of the positive clones was identified as pyridoxal phosphatase (PDXP) (GenBank accession number AY125047 and BC000320) (Jang et al, 2003). This enzyme dephosphorylates pyridoxal 5′-phosphate (PLP), an important cofactor for enzymes involved in vitamin B metabolism and in neurotransmitter biosynthesis.

METHODS AND SUBJECTS

Subjects

Subjects were obtained from 243 patients with lung cancer, 113 with different other types of cancers, 47 with multiple sclerosis (MS), 47 with type 1 diabetes, 72 with autoimmune Addison’s disease or autoimmune polyendocrine syndromes (APS) and 88 healthy blood donors.

Screening of the cDNA expression library

A human brain triplEx cDNA expression library (human brain 5′-Stretch Plus cDNA Library, Clontech, Palo Alto, CA, USA) was screened with serum from a patient with ovarian cancer and paraneoplastic cerebellar degeneration containing Yo antibodies using the method described by Rorsman et al (1995). Briefly, bacteria and the cDNA library were mixed on a Petri dish containing NZY agar. After about 3.5 h of culture, plaque appeared
Pyridoxal phosphatase: a novel cancer autoantigen
AS Boe et al.

Rabbit PDXP antiserum

Purified PDXP was dialysed against sterile phosphate-buffered saline (PBS). Two female outbred rabbits were immunised intradermally with about 50 μg of purified protein emulsified 1:1 in Freund’s complete adjuvant. The rabbits were boosted with about 30 μg of protein emulsified 1:1 in Freund’s incomplete adjuvant on days 14, 28, 56 and 86 after the primary immunisation. After reactivity towards the protein antigen was verified by RIA of radio labelled protein expressed by ITT (described above) and by Western blot (described below), the rabbits were terminally bled on day 96 and serum was collected.

Western blot

Recombinant PDXP (about 15 μg) was incubated in 4 × sample buffer and 10 × reducing agent and applied to the large well on a 4–12% NuPAGE Bis-Tris gel (Invitrogen, Mellebeke, Belgium). The molecular markers used were the high-range rainbow molecular weight marker (Amersham Pharmacia Biotech) for radio labelled samples and the SeeBlue Plus 2 prestained standard (Invitrogen) for nonlabelled samples. The proteins were blotted onto a Hybond P PVDF membrane (Amersham Pharmacia Biotech) and incubated with sera from 24 cancer patients that were positive for anti-PDXP in RIA or immunised rabbit serum diluted 1:100 in blocking buffer (PBS with 4% fat-free dry milk) and then with alkaline phosphatase-conjugated rabbit anti-human IgG (Sigma-Aldrich) and goat anti-rabbit IgG (Southern Biotech, Birmingham, AL, USA) diluted 1:3000 in blocking buffer. The substrate for alkaline phosphatase was 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BioRad).

Immunohistochemistry

We used autopsy material from a 69-year-old man, otherwise healthy, who had died from sudden cardiac arrest 24 h previously. Tissue from cerebrum, cerebellum, liver, kidney, spleen, heart, lung and muscle was taken from 2–3 locations in each organ, snap-frozen in isopentane cooled in liquid nitrogen and stored at −80°C until use. A total of 8 μm thick cryostat sections were incubated with the preimmunised or immunised rabbit sera against PDXP diluted 1:100 in PBS and then with Alexa Fluor goat anti-rabbit IgG (Molecular Probes, Eugene, OR, USA) diluted 1:100 in PBS. Analysis used a LEICA fluorescence microscope. In some experiments, sections of human brain were stained with rabbit anti-PDXP diluted 1:100 in PBS followed by peroxidase labelled anti-rabbit antibody and analysis by light microscopy. Tissue sections were incubated without prior fixation, as we experienced that fixation with acetone or formaldehyde prior to primary incubation did not result in enhanced staining.

Northern blot

In total, 20 μg of total RNA from rat cerebellum purified by the RNasey mini kit (Qiagen, Hilden, Germany), rat brain (Clontech) and of a pool of total RNA from a wide selection of human tissues (Human Reference total RNA; Clontech) were denatured, electrophoresed on a denaturing 1.2% formaldehyde agarose gel and blotted onto a Hybond N nylon membrane (Amersham Pharmacia Biotech) by capillary blotting in the presence of saline sodium citrate buffer (10 × SSC; 1.5 M NaCl, 0.15 M sodium citrate, pH 7.0). The membrane was washed in a buffer containing 1.6 × SSC and 0.2 M Tris-HCl pH 7.2 and baked at 80°C for 15 min, and the RNA was crosslinked to the membrane at 120 mJ using Stratallinker 1800 UV (Stratagene, La Jolla, CA, USA). Full-length PDXP cDNA (20 ng) was labelled with 4 μl of α-32P-dCTP (3000 μCi mmol−1, Perkin-Elmer, Boston, MA, USA) using the Megaprime kit.

Protein expression and purification

The protein was expressed as a 10 × His-tag fusion protein by the vector pET19b in the Escherichia coli strain Rosetta (DE3) pLysS (Novagen, Madison, WI, USA). In total, 500 ml of Luria-Bertani medium containing 50 μg ml−1 ampicillin was inoculated with 4 ml of an overnight culture of bacteria generated from a single colony of freshly transformed cells and incubated at 37°C. The bacterial culture was grown at 37°C, and protein expression was induced with 1 mM isopropyl-β-D-thiogalactoside at an optical density at 600 nm of 0.9. The cells were harvested 3.5 h later by centrifugation. Inclusion bodies were purified in the presence of complete, EDTA-free Protease Inhibitor Cocktail Tablets (Roche, Basel, Switzerland) using the B-PER Bacterial Protein Extraction Reagent (Pierce, Rockford, IL, USA) according to the manufacturer’s protocol. Inclusion bodies from a 75-ml culture were dissolved in 0.2 M Tris-HCl pH 7.2 and baked at 80°C. The solution was then centrifuged at 20,000 × g and filtered through a 0.45-μm syringe filter followed by nickel chelate chromatography using the A ¨ KTAprime chromatography system (Pierce, Rockford, IL, USA) according to the manufacturer’s protocol. Inclusion bodies were solubilised and filtered through a 0.45-μm syringe filter followed by nickel chelate chromatography using the A ¨ KTAprime chromatography system and of a pool of total RNA from a wide selection of human tissues (Human Reference total RNA; Clontech) were denatured, electrophoresed on a denaturing 1.2% formaldehyde agarose gel and blotted onto a Hybond N nylon membrane (Amersham Pharmacia Biotech) by capillary blotting in the presence of saline sodium citrate buffer (10 × SSC; 1.5 M NaCl, 0.15 M sodium citrate, pH 7.0). The membrane was washed in a buffer containing 1.6 × SSC and 0.2 M Tris-HCl pH 7.2 and baked at 80°C for 15 min, and the RNA was crosslinked to the membrane at 120 mJ using Stratallinker 1800 UV (Stratagene, La Jolla, CA, USA). Full-length PDXP cDNA (20 ng) was labelled with 4 μl of α-32P-dCTP (3000 μCi mmol−1, Perkin-Elmer, Boston, MA, USA) using the Megaprime kit.
(Amersham Pharmacia Biotech) and purified over a Sephadex G-50 (Amersham Pharmacia Biotech). The blot was wetted in 2× SSC and prehybridised for 1 h at 65°C in 16 ml of hybridisation buffer containing 2 mg ml⁻¹ bovine serum albumin, 2 mg ml⁻¹ Ficoll 400, 2 mg ml⁻¹ polyvinylpyrrolidone K25, 0.5 m NaH₂PO₄, 14 mg ml⁻¹ SDS, 1 mM EDTA, 5 mg of heat-denatured, sheared salmon sperm DNA (Sigma-Aldrich) and 30 μg of heat-denatured human Cot-1 DNA (Invitrogen). The probe was denatured by heat in 1 ml of hybridisation buffer, added to the hybridisation solution used for prehybridisation and incubated with the membrane at 65°C overnight. The hybridised membrane was then washed four times at 65°C for 30 min in a washing buffer (20 mM NaH₂PO₄ pH 7.2 and 5 mg ml⁻¹ SDS) and exposed to Kodak BioMax MS Film (Eastman Kodak Company, New Haven, CT, USA) at −80°C for 2 days using BioMax TranScreen HE intensifying screen (Eastman Kodak Company).

Expression studies

Gene expression in human tissues of the isolated cDNA was determined by hybridising cDNA with the Multiple Tissue Expression Array (Clontech). Full-length coding cDNA was labelled with α⁻³²P-dCTP, hybridised against the Multiple Tissue Expression Array and developed as described for Northern blots. In addition, rabbit PLP phosphatase antiserum (described above) diluted 1:500 was applied to the Newborn Rat Brain Protein Explorer (Alpha Diagnostic International, San Antonio, TX, USA), a commercial ready-made membrane containing brain proteins from rats. Hybridisations were detected using chemiluminescence following the instructions of the manufacturer, except that donkey anti-rabbit horseradish peroxidase-coupled IgG (H + L) (Jackson Immunoresearch, West Grove, PA, USA) and the SuperSignal West Femto Maximum Sensitivity Substrate chemiluminescence kit (Pierce) were used for detection instead of the reagents in the kit. The membrane was exposed for 15 min on a IMAGE Station 2000R (Eastman Kodak Company).

Statistical analysis

Differences between groups were assessed using the Pearson χ² test.

Ethical considerations

The study has been carried out with ethical committee approval. For animal experiments, United Kingdom co-ordinating committee on cancer research (UKCCCR) guidelines for the Welfare of Animals in Experimental Neoplasia were followed (Workman et al). The study was performed according to the Declaration of Helsinki.

RESULTS

Identification of a novel autoantigen

Screening the cDNA library with the PND serum revealed a positive clone that was isolated and sequenced. The nucleotide sequence showed that the clone was identical to a truncated form of PDXP that covered amino-acid codons 122–297 (GenBank accession number AY125047) (Fonda, 1992; Gao and Fonda, 1994a–c; Fonda and Zhang, 1995; Jang et al, 2003). Full-length cDNA for PDXP was ordered from the I.M.A.G.E Consortium and subcloned into the pET19b vector. The full-length coding sequence contained 891 nucleotides and encoded a protein of 297 amino acids with a molecular weight of 32 kDa.

Expression of recombinant PDXP and production of antibodies against PDXP

We expressed PDXP as ³⁵S-labelled protein using ITT (Figure 1A). The protein was also expressed in E. coli and purified to about 95% as judged by SDS–PAGE (Figure 1B). The molecular weight of the ITT-expressed protein correlated with the weight of the bacterially
expressed PDXP. Purified *E. coli*-expressed protein was used to immunise a rabbit in order to achieve antibodies against PDXP. One immunised rabbit produced a high-titre antiserum against PDXP as assessed by RIA and Western blot, whereas serum from the preimmunised rabbit did not bind the protein.

**Tissue expression of PDXP**

Northern blot of radioactive-labelled full-length PDXP against RNA pools of different origins revealed that the molecular weight of the messenger RNA was about 2 kb (Figure 2) (Jang et al., 2003). The results from mRNA multitissue expression level analysis of PDXP using polyA RNA dot blot indicated that the PDXP gene was strongly expressed in different parts of the central nervous system and also to some extent in testis, liver, kidney and cancer cell lines (Figure 3). Most of the other tissues represented on the blot also expressed PDXP but to a lesser degree than in the neuronal tissue. These results were supported by results obtained from analysis of the brain ReadyBlot explorer kit (data not shown).

![Figure 3](image-url)

*Figure 3* Expression of PDXP in various human normal tissues and cancer cell lines. The PDXP cDNA was labelled with *α*-32P-dCTP and hybridised against the Multiple Tissue Expression Array consisting of normalised, polyA RNA spotted on a nylon membrane as denoted in (B) PDXP transcripts are most abundant in the nervous system (columns 1–3) (A). The cDNA probe hybridised with *E. coli* DNA, probably due to several identical nucleotide stretches.
Autoantibodies against PDXP in patients with cancer, autoimmune disease and controls

Altogether, 22 of 243 (9.1%) lung cancer patients and eight of 113 (7.1%) patients with various other types of cancer had autoantibodies against PDXP (Figure 4), whereas two of 88 (2.3%) sera from healthy controls revealed reactivity ($P = 0.046$ when comparing all cancer patients with healthy controls). In addition, one of 47 (2.1%) patients with type 1 diabetes (three of 72 (4.1%) patients with autoimmune Addison’s disease or APS and two of 47 (4.5%) MS patients had autoantibodies against PDXP (Figure 4) ($P = 0.008$ when comparing all four control groups with all cancer patients). Clinical data were only available from some of the cancer patients with PDXP antibodies, and no PND was discovered in these. Onconeuronal antibodies (anti-Hu) were detected in five of the anti-PDXP positive sera from the patients with lung cancer using immunofluorescence and immunoblot. None of the antibody-positive patients with Addison’s disease, APS, diabetes or MS had known malignant disease. Among the patients with sera containing PDXP antibodies detected by RIA, five of 15 (33%) patients with lung cancer and three of eight (38%) patients with various types of cancer recognised PDXP by Western blot.

Immunohistochemistry

The rabbit antisera against PDXP stained human cerebrum and cerebellum but not liver, spleen, lung, heart, kidney and muscle (data not shown). Anti-PDXP stained the cytoplasm of microglia (Figure 5) and astrocytes. Neurons also stained weakly.

DISCUSSION

This study identified PDXP as a novel autoantigen associated with various types of cancer, including lung cancer. In total, 9% of patients with lung cancer and 7% of patients with other types of cancer revealed reactivity against PDXP vs 2% among healthy controls. In the immunoprecipitation experiments, some sera reacted with native proteins and failed to recognise proteins that had been frozen (data not shown). This may imply that the protein changed its conformation after freezing and thawing and that autoantibodies recognise conformational epitopes. This speculation is supported by the finding that only a subgroup of the patients positive in the RIA assay showed reactivity in Western blot. RIA seems to be a more sensitive method for detecting autoantibodies, similar to the findings with anti-Hu (Storstein et al, 2004) and antiinsulin (Sodoyez-Goffaux et al, 1988). Five of the lung cancer patients positive for anti-PDXP also had circulating Hu-antibodies but not clinically evident PND. Onconeuronal antibodies were not detected in any of the other anti-PDXP positive sera. Our findings therefore indicate that PDXP is associated with cancer and not with PND, but the latter association cannot be ruled out.

Autoantibodies against several different proteins are frequent in cancer patients, and most appear in a wide variety of types of
cancer (Tan and Shi, 2003; Zhang et al, 2003), similar to our findings of anti-PDXP. Autoantibodies against the cell cycle checkpoint protein p53, for example, are found in 9–20% of human cancer patients with a specificity of 96% (Sousi, 2000). Hu and VGCC antibodies were not related to improved survival in patients with small-cell lung cancer (Monstad et al, 2004). The effects of circulating autoantibodies against PDXP are still unclear. Future studies on more well-defined patient materials should elucidate the sensitivity and specificity of the association between antibodies against PDXP and cancer. Our finding of an increased frequency among patients with Addison’s disease, APS and MS compared with controls may imply other associations than cancer.

It would also be interesting to determine whether anti-PDXP in patients affects the course and prognosis of malignant disease.

The recent study by Jang et al (2003) revealed that the expression of PDXP is ubiquitous, although with higher levels in the central nervous system, testis and liver. This is in agreement with our results. We found high expression in the central nervous system but also in a number of cancer cell lines, which could explain why PDXP becomes an autoantigen in patients with cancer. The PLP level in various tissues is regulated by several enzymes: PDXP, pyridoxal kinase, pyridoxamine-5′-phosphate oxidase and various binding proteins (Anderson et al, 1974; Li et al, 1974; Harris, 1990; Fonda, 1992). The brain contains an especially high concentration of PLP, and this is where the highest expression of PDXP is. More than 140 distinct enzymatic reactions depend on PLP according to the Enzyme Commission (http://www.chem.qmul.ac.uk/iubmb/enzyme) (Percudani and Peracchi, 2003), including many enzymes that participate in the biosynthesis of important neurotransmitters. Examples of the latter are glutamate decarboxylase participating in the synthesis of GABA and aromatic L-amino acid decarboxylase participating in the biosynthesis of catecholamines and serotonin. Interestingly, these enzymes have recently been found to be autoantigens in nervous system and endocrine diseases. Antibodies against glutamate decarboxylase (Lindefors, 1993) are found in type 1 diabetes (Baekkeskov et al, 1990), stiff-man syndrome (Solimena et al, 1990) and APS type I (Velloso et al, 1994). Autoantibodies against aromatic L-amino acid decarboxylase (Rorsman et al, 1995), histidine decarboxylase (Sköldberg et al, 2003) and cysteine sulfinate decarboxylase (Sköldberg et al, 2004) are all found in patients with APS type I. We have now shown that another enzyme related to PLP is an autoantigen, making PLP a common denominator for enzymes targeted by the immune system in endocrine and nervous system autoimmune diseases.

The reason why the immune system recognises PDXP and other PLP-associated autoantigens as non-self remains obscure. PLP, which is the coenzymatically active form of vitamin B6 (pyridoxine), is reported to suppress tumorigenesis, such as in colon cancer (Matsubara et al, 2003). The mechanisms behind the chemopreventive effect of vitamin B6 probably combine inhibitory effects on cell proliferation, oxidative stress and angiogenesis. One theory is that some tumours express elevated levels of PDXP to overcome the suppressive effect of vitamin B6. The increased expression might induce a break in immune tolerance against PDXP. The Multiple Tissue Expression Array revealed that some cancer cell lines express PDXP. PLP has also recently been suggested to have immunomodulatory properties because it binds very tightly to the D1 domain of CD4 on T cells, thereby interfering with proper interaction between CD4 and the major histocompatibility complex class II (Salhany and Schopfer, 1993). Lack of interaction leads to T-cell apoptosis and anergy to autoantigens (Namazi, 2003). One might speculate increased expression of PDXP degrade PLP, thereby facilitating tumour growth, but this could also lead to an enhanced immune response against the tumour.

In conclusion, PDXP is a novel autoantigen associated with cancer. PLP seems to be a common denominator for autoantigens involved in nervous system and endocrine autoimmune diseases. The clinical implications of anti-PDXP remain to be defined.

ACKNOWLEDGEMENTS

Anette Boe is a fellow of the Research Council of Norway. We thank Mette Haugen, Department of Neurology, and Elin Theodorsen and Kristin Moen, Division of Endocrinology, Haukeland University Hospital, for excellent technical assistance. We also thank Lars Bø, Department of Neurology, Haukeland University Hospital, for help with immunohistochemical studies. We are indebted to Lars Drivsholm, Department of Oncology and Hematology, Næstved Hospital, Denmark, for providing sera from patients with lung cancer. The study was supported by grants from Innovest and Haukeland University Hospital.

REFERENCES

Anderson BB, Newmark PA, Rawlins M, Green R (1974) Plasma binding of vitamin B6 compounds. Nature 250: 502–504
Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Fonda ML (1992) Purification and characterization of vitamin B6-phosphate phosphatase from human erythrocytes. Arch Biochem Biophys 290: 267–279
Covini G, Chen EK, Nishioka M, Morshed SA, Reed SI, Tan EM (1997) Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology 25: 75–80
Crawford LV, Pin DC, Bulbrook RD (1982) Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403–408
Dalmaj JO, Posner JB (1997) Paraneoplastic syndromes affecting the nervous system. Semin Oncol 24: 318–328
Falorni A, Nikoshkov A, Laureti S, Gorenback E, Hulting AL, Casucci G, Santusiano F, Brunetti P, Luthman H, Lernmark A (1995) High diagnostic accuracy for idiopathic Addison’s disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. J Clin Endocrinol Metab 80: 2752–2755
Fonda ML (1992) Purification and characterization of vitamin B6-phosphate phosphatase from human erythrocytes. J Biol Chem 267: 15978–15983
Fonda ML, Zhang YN (1995) Kinetic mechanism and divalent metal activation of human erythrocyte pyridoxal phosphate phosphatase. Arch Biochem Biophys 320: 345–352
Gao G, Fonda ML (1994a) Identification of an essential cysteine residue in pyridoxal phosphate from human erythrocytes. J Biol Chem 269: 8234–8239
Gao GJ, Fonda ML (1994b) Evidence for a phosphoenzyme intermediate formed during catalysis by pyridoxal phosphate from human erythrocytes. Arch Biochem Biophys 313: 166–172
Harris H (1990) The human alkaline phosphatases: what we know and what we don’t know. Clin Chim Acta 186: 133–150
Jang YM, Kim DW, Kang TC, Won MH, Baek NI, Moon BJ, Choi SY, Kwon OS (2003) Human pyridoxal phosphate: molecular cloning, functional expression and tissue distribution. J Biol Chem 278: 50040–50046
Matsubara K, Komatsu S, Oka T, Kato N (2003) Vitamin B6-mediated Lindefors N (1993) Dopaminergic regulation of glutamic acid decarboxylase mRNA expression and GABA release in the striatum: a review. Prog Neuropsychopharmacol Biol Psychiatry 17: 887–903
Matsubara K, Komatsu S, Oka T, Kato N (2003) Vitamin B6-mediated suppression of colon tumorigenesis, cell proliferation, and angiogenesis (review). J Nutr Biochem 14: 246–250
Monstad SE, Drivsholm L, Storstein A, Aarseth JH, Haugen M, Lang B, Vincent A, Vedeler CA (2004) Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol 22: 795–800
Namazi MR (2003) Pyridoxal 5′-phosphate as a novel weapon against autoimmunity and transplant rejection. FASEB J 17: 2184–2186
Percudani R, Perauci A (2003) A genomic overview of pyridoxal-phosphate-dependent enzymes. EMBO Rep 4: 850–854
Rorsman F, Husebye ES, Winqvist O, Bjork E, Karlsson FA, Kampe O (1995) Aromatic L-amino-acid decarboxylase, a pyridoxal phosphate-dependent enzyme, is a beta-cell autoantigen. Proc Natl Acad Sci USA 92: 8626–8629
Salhany JM, Schopfer LM (1993) Pyridoxal 5′-phosphate binds specifically to soluble CD4 protein, the HIV-1 receptor. Implications for AIDS therapy. J Biol Chem 268: 7643–7645
Skoldberg F, Portela-Gomes GM, Grimalius L, Nilsson G, Perheentupa J, Betterle C, Husebye ES, Gustafsson J, Ronnbloem A, Rorsman F, Kampe O (2003) Histidine decarboxylase, a pyridoxal phosphate-dependent enzyme, is an autoantigen of gastric enterochromaffin-like cells. J Clin Endocrinol Metab 88: 1445–1452
Skoldberg F, Rorsman F, Perheentupa J, Landin-Olsson M, Husebye ES, Gustafsson J, Husebye ES, Kampe O (2004) Analysis of antibody reactivity against cysteine sulfenic acid decarboxylase, a pyridoxal phosphate-dependent enzyme, in endocrine autoimmune disease. J Clin Endocrinol Metab 89: 1636–1640
Sodoyez-Goffaux F, Koch M, Dozio N, Brandenburg D, Sodoyez JC (1988) Advantages and pitfalls of radioimmune and enzyme linked immunosorbent assays of insulin antibodies. Diabetologia 31: 694–702
Solimena M, Follì F, Aparisi R, Pozza G, De Camilli P (1990) Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 322: 1555–1560
Soussi T (2000) p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60: 1777–1788
Souza SL, Montalli Da Assumpcao LV, Ward LS (2003) Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer. Thyroid 13: 491–495
Storstein A, Monstad SE, Nakkestad HL, Husebye ES, Vedeler CA (2004) Paraneoplastic antibodies against HuD detected by a sensitive radio-binding assay. J Neurol 251: 197–203
Tan EM, Shi FD (2003) Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin Exp Immunol 134: 169–177
Trivers GE, De Benedetti VM, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, Harris CC (1996) Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 2: 1767–1775
Velloso LA, Winqvist O, Gustafsson J, Kampe O, Karlsson FA (1994) Autoantibodies against a novel 51 kDa islet antigen and glutamate decarboxylase isoforms in autoimmune polyendocrine syndrome type I. Diabetologia 37: 61–69
Workman P, Twertonman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J. United Kingdom co-ordinating committee on cancer research (UKCCCR) guidelines for the Welfare of Animals in Experimental Neoplasia
Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM (2003) Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12: 136–143
Zhang JY, Chan EK, Peng XX, Tan EM (1999) A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 189: 1101–1110